Shigatoxin-associated hemolytic uremic syndrome: Current molecular mechanisms and future therapies

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 195-208

  Keir, Lindsay S ^a   Marks, Stephen D ^b   Kim, Jon Jin ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Great Ormond Street Hospital NHS Foundation Trust ^*  (United Kingdom)

Author keywords

Alternative pathway; Complement; Diarrhea; Eculizumab; Escherichia coli; Hemolytic uremic syndrome; Shigatoxin

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COMPLEMENT INHIBITOR; COTRIMOXAZOLE; ECULIZUMAB; ERYTHROMYCIN; FOSFOMYCIN; FRESH FROZEN PLASMA; HYDROCORTISONE; METRONIDAZOLE; PROSTACYCLIN; SHIGA TOXIN; SULFONAMIDE; VASCULOTROPIN A; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DISEASE COURSE; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOADSORPTION; MOLECULAR PATHOLOGY; NONHUMAN; NUTRITIONAL SUPPORT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ACUTE KIDNEY FAILURE; ANIMAL; BACTERIAL INFECTION; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL DISEASE; METHODOLOGY; MICROBIOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BACTERIAL INFECTIONS; CHILD; GASTROINTESTINAL DISEASES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSORBENT TECHNIQUES; PLASMA EXCHANGE; SHIGA TOXINS;

EID: 84867911677     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S25757     Document Type: Review

References (108)

1. Scheiring J, Andreoli S P, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23:1749-1760.
2. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003;290:1360-1370.
3. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005;115:e673-e680.
4. Verweyen HM, Karch H, Brandis M, Zimmerhackl LB. Enterohemorrhagic Escherichia coli infections: following transmission routes. Pediatr Nephrol. 2000;14:73-83.
5. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035-1050.
6. Taylor CM. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008;23:1425-1431.
7. Lynn RM, O'Brien SJ, Taylor CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis. 2005;11:590-596.
8. Frank C, Werber D, Cramer JP; for HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771-1780.
9. Gianviti A, Tozzi AE, De Petris L, et al. Risk factors for poor renal prognosis in children with hemolytic uremic syndrome. Pediatr Nephrol. 2003;18:1229-1235.
10. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218-1228.
11. Donnerstag F, Ding X, Pape L, et al. Patterns in early diffusionweighted MRI in children with haemolytic uraemic syndrome and CNS involvement. Eur Radiol. 2012;22:506-513.
12. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child. 2001;84:434-435.
13. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010;25:2231-2240.
14. Zumbrun SD, Hanson L, Sinclair JF, et al. Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate shiga toxin receptor globotetraosylceramide. Infect Immun. 2010;78:4488-4499.
15. Brigotti M, Tazzari PL, Ravanelli E, et al. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr Infect Dis J. 2011;30:486-490.
16. Schüller S. Shiga toxin interaction with human intestinal epithelium. Toxins. 2011;3:626-639.
17. Griener T P, Mulvey GL, Marcato P, Armstrong GD. Differential binding of shiga toxin 2 to human and murine neutrophils. J Med Microbiol. 2007;56:1423-1430.
18. Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR. Shiga toxin binds to activated platelets. J Thromb Haemost. 2004;2:499-506.
19. Bitzan M, Richardson S, Huang C, Boyd B, Petric M, Karmali MA. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun. 1994;62:3337-3347.
20. Psotka MA, Obata F, Kolling GL, et al. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun. 2009;77:959-969.
21. Ergonul Z, Hughes AK, Kohan DE. Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1. J Infect Dis. 2003;187:154-158.
22. Mattocks M, Bagovich M, De Rosa M, et al. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J. 2006;273:2064-2075.
23. Johannes L, Römer W. Shiga toxins - from cell biology to biomedical applications. Nat Rev Microbiol. 2010;8:105-116.
24. Spooner RA, Lord JM. How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum. Curr Top Microbiol Immunol. 2012;357:19-40.
25. Brigotti M, Alferi R, Sestili P, et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 2002;16:365-372.
26. Zoja C, Angioletti S, Donadelli R, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int. 2002;62:846-856.
27. Morigi M, Galbusera M, Binda E, et al. Verotoxin-1-induced upregulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98: 1828-1835.
28. Müthing J, Schweppe CH, Karch H, Friedrich AW. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 2009;101:252-264.
29. Fraser ME, Fujinaga M, Cherney MM, et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem. 2004;279:27511-27517.
30. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem. 1993;268:15484-15488.
31. Bauwens A, Bielaszewska M, Kemper B, et al. Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost. 2011;105:515-528.
32. Mahfoud R, Manis A, Lingwood CA. Fatty acid-dependent globotriaosyl ceramide receptor function in detergent resistant model membranes. J Lipid Res. 2009;50:1744-1755.
33. Khan F, Proulx F, Lingwood CA. Detergent-resistant globotriaosyl ceramide may defne verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. Kidney Int. 2009;75:1209-1216.
34. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3:249-277.
35. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831-846.
36. Fernández GC, Te Loo M W, van der Velden TJ, van der Heuvel L P, Palermo MS, Monnens LL. Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. Pediatr Nephrol. 2003;18:1066-1068.
37. Nolasco LH, Turner NA, Bernardo A, et al. Hemolytic uremic syndromeassociated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large vonWillebrand factor multimers. Blood. 2005;106:4199-4209.
38. Murata K, Higuchi T, Takada K, Oida K, Horie S, Ishii H. Verotoxin-1stimulation of macrophage-like THP-1 cells upregulates tissue factor expression through activation of c-Yes tyrosine kinase: possible signal transduction in tissue factor upregulation. Biochim Biophys Acta. 2006;1762:835-843.
39. Hughes AK, Stricklett PK, Schmid D, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int. 2000;57:2350-2359.
40. De Petris L, Patrick J, Christen E, Trachtman H. Urinary podocyte mRNA excretion in children with D+HUS: a potential marker of longterm outcome. Ren Fail. 2006;28:475-482.
41. Hughes AK, Stricklett PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int. 1998;54:426-437.
42. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol. 2010;25:2431-2442.
43. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
44. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26.
45. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53:836-844.
46. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41:e84.
47. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003;100:12966-12971.
48. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci. 2007;104: 240-245.
49. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112:4948-4952.
50. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357.
51. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687.
52. Jokiranta TS, Zipfel P F, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical haemolytic uremic syndrome? Mol Immunol. 2007;44:3889-3900.
53. Robson WL, Leung AK, Fick GH, McKenna AI. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron. 1992;62:296-299.
54. Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol. 1980;13:168-171.
55. Thurman JM, Marians R, Emlen W, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1920-1924.
56. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol. 2009;182:6394-6400.
57. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180.
58. Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliinduced hemolytic uremic syndrome. Blood. 2011;117:5503-5513.
59. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008;111:624-632.
60. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364: 2561-2563.
61. Rasko DA, Webster DR, Sahl J W, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med. 2011;365:709-717.
62. Nitschke M, Sayk F, Härtel C, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA. 2012;307:1046-1052.
63. Turner M. German E. coli outbreak leads to drug trial. Available from: http://www.nature.com/news/2011/110527/full/news.2011.332.html. Accessed May 26, 2012.
64. Proulx F, Turgeon J P, Delage G, Lafeur L, Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157: H7 enteritis. J Pediatr. 1992;121:299-303.
65. Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State. The frst year of statewide disease surveillance. JAMA. 1989;262:355-359.
66. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE. A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Nephrol. 1994;42:85-89.
67. Bell B P, Griffn PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 1997;100:E12.
68. Slutsker L, Ries AA, Maloney K, Wells JG, Greene KD, Griffn PM. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis. 1998;177:962-966.
69. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2001;33:923-931.
70. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009;1:CD003595.
71. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol. 1999;52:357-362.
72. Yo h M, Frimpong EK, Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 1997;19:57-64.
73. Kurioka T, Yunou Y, Harada H, Kita E. Effcacy of antibiotic therapy for infection with Shiga-like toxin producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis. 1999;18:561-571.
74. Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis. 2000;181:664-670.
75. Ichinohe N, Ohara-Nemoto Y, Nemoto TK, Kimura S, Ichinohe S. Effects of fosfomycin on Shiga toxin-producing Escherichia coli: quantifcation of copy numbers of Shiga toxin-encoding genes and their expression levels using real-time PCR. J Med Microbiol. 2009;58:971-973.
76. Pavia AT, Nichols CR, Green D P, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr. 1990;116:544-551.
77. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930-1936.
78. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J. 2012;31:37-41.
79. Kimmitt PT, Harwood CR, Barer MR. Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet. 1999;353:1588-1589.
80. Kimmitt P, Harwood C, Barer M. Toxin gene expression by Shiga toxin producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis. 2000;6:458-465.
81. Grif K, Dierich M P, Karch H, Allerberger F. Strain specifc differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998;17:761-766.
82. Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T, Nasu M. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents. 2000;15:103-109.
83. Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2007;51:2837-2841.
84. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-4069.
85. Waters AM, Licht C. Atypical HUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57.
86. Kim JJ, Goodship TH, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol. 2011;26:2073-2076.
87. Loirat C, Sonsino E, Hinglais N, Jais J P, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1988;2:279-285.
88. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988;112:284-290.
89. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354:1327-1330.
90. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011;378:1089-1093.
91. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological defcits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet. 2011;378:1166-1173.
92. Staudt A, Böhm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation. 2002;106:2448-2453.
93. Ward DM. Conventional apheresis therapies: a review. J Clin Apher. 2011;26:230-238.
94. Karmali MA. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. J Infect Dis. 2004;189:355-359.
95. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis. 1990;162:553-556.
96. Tarr PI. Basic fbroblast growth factor and Shiga toxin-O157:H7-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2002;13:817-820.
97. Nishikawa K. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli. Arch Immunol Ther Exp. 2011;59:239-247.
98. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxinbinding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA. 2003;290:1337-1344.
99. Armstrong GD, McLaine PN, Rowe PC. Clinical trials of synsorb Pk in preventing hemolytic uremic syndrome. In: Kaper JB, O'Brien AD, editors. Escherichia coli O157:H and Other Shiga Toxin-producing E. coli Strains. Washington, DC: American Society for Microbiology Press; 1998.
100. Nishikawa K, Koji M, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci U S A. 2002;99:7669-7674.
101. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature. 2000;403:669-672.
102. Mulvey G, Marcato P, Kitov P, Sadowska JM, Bundle DR, Armstrong GD. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis. 2003;187:640-669.
103. López EL, Contrini MM, Glatstein E, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:239-243.
104. Nishikawa K, Watanabe M, Kita E, et al. A multivalent peptide library approach identifes a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 2006;20:2597-2599.
105. Stearns-Kurosawa DJ, Collins V, Freeman S, et al. Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. Pediatr Nephrol. 2011;26:2031-2039.
106. Foster RR. The importance of cellular VEGF bioactivity in the development of glomerular disease. Nephron Exp Nephrol. 2009;113:e8-e15.
107. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular fltration barrier. Nephron Physiol. 2007;106:32-37.
108. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol. 2011;26(4):523-33.